News

Applied UV Announces it is Receiving Over $2 Million Cash Deposits for Over $4 Million Order From Large Developers, Validating Our Strategy to Reduce Dependence on China

NEW YORK, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Applied UV, Inc. (NASDAQ: AUVI), a pioneer in…

1 year ago

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due…

1 year ago

MiNK Therapeutics Reports Second Quarter 2023 Results

-  Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center -  iNKT…

1 year ago

Optimi Health Announces CAD $3,000,000 Senior Debt Financing

First Tranche of CAD $1,000,000 Secured From Chairman JJ Wilson’s Catcher Investments Ltd. JJ Wilson Director and non-executive Chair of…

1 year ago

Alimera Sciences Reports Second Quarter 2023 Results

Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5…

1 year ago

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical…

1 year ago

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor…

1 year ago

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second…

1 year ago

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human…

1 year ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug.…

1 year ago